Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Bank Julius Baer & Co. Ltd Zurich

Bank Julius Baer & Co. Ltd Zurich lowered its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 46.8% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 98,269 shares of the company’s stock after selling 86,321 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich’s holdings in Moderna were worth $4,509,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. State Street Corp raised its position in shares of Moderna by 12.1% during the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock worth $1,125,899,000 after purchasing an additional 1,823,276 shares during the period. Wellington Management Group LLP raised its position in shares of Moderna by 21.0% during the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after purchasing an additional 906,114 shares during the period. Two Sigma Advisers LP acquired a new stake in shares of Moderna during the 3rd quarter worth approximately $23,825,000. Douglas Lane & Associates LLC raised its position in shares of Moderna by 62.9% during the 4th quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company’s stock worth $32,175,000 after purchasing an additional 298,715 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Moderna by 9.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,344,203 shares of the company’s stock worth $97,472,000 after purchasing an additional 211,426 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on MRNA. HSBC upgraded Moderna from a “hold” rating to a “buy” rating and set a $58.00 price target on the stock in a research report on Monday, November 18th. UBS Group decreased their price objective on Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a report on Wednesday, February 19th. Leerink Partners decreased their price objective on Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a report on Thursday, January 16th. Royal Bank of Canada reissued a “sector perform” rating and issued a $40.00 price objective on shares of Moderna in a report on Tuesday, February 18th. Finally, The Goldman Sachs Group lowered Moderna from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $99.00 to $51.00 in a report on Wednesday, January 29th. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $60.63.

Moderna Stock Up 3.8 %

MRNA opened at $35.61 on Monday. The firm has a market cap of $13.74 billion, a PE ratio of -3.84 and a beta of 1.86. The business has a fifty day simple moving average of $36.60 and a 200-day simple moving average of $48.77. Moderna, Inc. has a fifty-two week low of $29.25 and a fifty-two week high of $170.47.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.